Should Everyone Be On A GLP-1?
from SIGNIFICANT. Hosted by David S. Filippi, MD
Join Dr. David S. Filippi as he explores the cutting-edge science of GLP-1 agonists—medications originally designed for diabetes but now revolutionizing weight management. From the intricate brain pathways that regulate hunger to the real-world health impacts of obesity, discover why GLP-1 agonists like semaglutide and tirzepatide are being hailed as game-changers. Visit significant-podcast.com for more insights and episodes.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of SIGNIFICANT.?
This episode is 46 minutes long.
When was this SIGNIFICANT. episode published?
This episode was published on November 3, 2024.
Can I download this SIGNIFICANT. episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.